Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 976 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endothelial Clear all

Conditions: Type 1 Diabetes Mellitus
Interventions: Vitamin C, Vitamin E; Dietary Supplement
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 8 Years to 15 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: HIV, Inflammation, Atherosclerosis
Interventions: Folic Acid, Placebo, Low Dose Methotrexate; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Middle-aged Subjects, Obesity & Overweight
Interventions: High Palmitic Acid Diet, Stearic Acid Test Meal, Oleic Acid Test Meal, High Stearic Acid Diet, High Oleic Acid Diet, Palmitic Acid Test Meal; Other
Lead sponsor: Florida State University; Other
Eligibility: 40 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Cardiovascular Disease
Interventions: ALT-711 (alagebrium chloride); Drug
Lead sponsor: Synvista Therapeutics, Inc; Industry
Eligibility: 50 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Retinal Vasculitis
Interventions: aflibercept 2 mg; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 550,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Head and Neck Cancer, Pharynx Cancer
Interventions: Chemoradiotherapy, Cisplatin, Bevacizumab, Erlotinib; Radiation · Drug
Lead sponsor: David M. Brizel, MD; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Aging, Endothelial Dysfunction, Senescence
Interventions: Supplement with ginger extract, L-citrulline, Paullinia cupana, and muira puama; Dietary Supplement
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Los Angeles, California • Santa Monica, California

Conditions: Fuchs' Endothelial Dystrophy
Interventions: Ripasudil hydrochloride hydrate 0.4% ophthalmic solution; Drug
Lead sponsor: Marian Macsai, MD; Other
Eligibility: 18 Years to 91 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Glenview, Illinois

Conditions: Growth Hormone Deficiency, Panhypopituitarism, Short Stature
Interventions: growth hormone; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 8 Years to 18 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Type 2 Diabetes Mellitus
Interventions: Exenatide, Glargine Insulin; Drug
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Traumatic Brain Injury
Interventions: Erythropoietin; Drug
Lead sponsor: Uniformed Services University of the Health Sciences; Federal
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy, Hypercholesterolemia, Hypertension
Interventions: investigate the relationship between in vivo and in vitro vascular responses; Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Blood Pressure, Endothelial Dysfunction
Interventions: Plant based bioequivalent Nitrate supplementation, Placebo; Dietary Supplement
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 40 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Torrance, California

Conditions: Fuchs' Dystrophy, Corneal Edema
Interventions: loteprednol etabonate, prednisolone acetate 1%; Drug
Lead sponsor: Cornea Research Foundation of America; Other
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Fuchs' Endothelial Dystrophy
Interventions: Netarsudil Ophthalmic; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 40 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Erectile Dysfunction, Hypogonadism, Male, Endothelial Dysfunction
Interventions: Daily low-dose PDE5 inhibitor therapy, Testosterone therapy as per clinical guidelines.; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: End Stage Renal Failure on Dialysis, Complication of Hemodialysis
Interventions: Placebo, Ramipril, Valsartan; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions: Dapagliflozin 10mg, Saxagliptin 5mg, Placebo Oral Tablet; Drug
Lead sponsor: Sabyasachi Sen; Other
Eligibility: 30 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Inflammation
Interventions: aldosterone, low or high sodium diet, placebo; Drug · Dietary Supplement
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Type 2 Diabetes Mellitus
Interventions: acipimox, placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV, Endothelial Dysfunction
Interventions: Not listed
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 8 Years to 30 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Obesity, Diabetes
Interventions: home-delivered meals, diabetes education for 12 months; Dietary Supplement · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 65 Years to 85 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Breast Cancer, Lymphoma, Chemotherapy Effect
Interventions: Arterial blood pressure, Vascular Ultrasound, Venous blood sample, Skin microcirculatory blood flow; Other
Lead sponsor: Carl Ade, M.S., Ph.D.; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Manhattan, Kansas

Conditions: Parenteral Nutrition
Interventions: ClinOleic 20% Intravenous Emulsion, Intralipid, 20% Intravenous Emulsion; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Atlanta, Georgia

Search by objective public record fields.

Effects of Vitamin C and E on Endothelial Function in Adolescent Diabetes

PET/CT Imaging Companion Study To ACTG A5314

Stearic Acid and Endothelial Function

STRETCH Study: Effect of Distensibility on Endothelial-Dependent Vasoreactivity in Patients With ISH

A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)

Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer

Effect of a Daily Supplement on Plasma PAI-1 Levels

Glanatec(R) for Descemet Stripping in Fuch's Endothelial Dystrophy

Growth Hormone and Endothelial Function in Children

The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes

Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Subacute TBI

Study of the Response of Human Small Blood Vessels

Effect of Inorganic Nitrate Supplement on Blood Pressure

Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty

Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty

EndoPAT Device for Endothelial Dysfunction in ED

Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis

Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus

Studies on Aldosterone and Vascular Function

Free Fatty Acids and Vascular Function in Subjects With Diabetes

Use of EndoPAT for Measurements of Endothelial Dysfunction in HIV Infected Children and Healthy Controls

Study of a Home Delivered Meal Program on Obese Elderly African American Subjects With Type 2 Diabetes Mellitus (DM)

The Effects of Anthracycline-based Chemotherapy on Peripheral Vascular Function

Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN